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Abstract
Background: Pulmonary hypertension is caused by a heterogenous group of disorders with
diverse pathophysiological mechanisms, with ultimate structural changes in the pulmonary
vascular bed. Platelet activation plays an important role in the development of pulmonary
arterial hypertension, while it is unknown whether it contributes to pathogenesis in other
conditions. We aimed to investigate platelet activation in different causes of pulmonary hyper-
tension by means of mean platelet volume measurement.
Methods: A total of 67 patients with different causes of pulmonary hypertension, and 31 controls,
were retrospectively reviewed. Patients with pulmonary hypertension were further grouped
according to underlying disease, including pulmonary arterial hypertension, pulmonary hyper-
tension due to left ventricular failure, and pulmonary hypertension due to chronic obstructive
pulmonary disorder. All patients and controls’ past medical data, admission echocardiograms
and complete blood counts were reviewed.
Results: Patients with pulmonary hypertension had higher mean platelet volume levels com-
pared to healthy controls (8.77 ± 1.18 vs 7.89 ± 0.53; p < 0.001), and statistical significance
was still present when pulmonary arterial hypertension patients were not included in the
pulmonary hypertension group (8.59 ± 1.23 vs 7.89 ± 0.53; p < 0.001). Among patients with
pulmonary hypertension, the pulmonary arterial hypertension group and the pulmonary hyper-
tension due to left ventricular failure group had higher mean platelet volumes compared to
healthy controls. Mean platelet volume did not correlate with pulmonary artery pressure.
Conclusions: Our results indicate that mean platelet volume is not only elevated in pulmo-
nary arterial hypertension, but also due to other causes of pulmonary hypertension. (Cardiol J
2012; 19, 2: 180–187)
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Introduction
Pulmonary hypertension (PH) is defined as
elevation of resting pulmonary artery pressure
(PAP) above 25 mm Hg, as measured by right heart
catheterization [1]. As PH is a hemodynamic defi-
nition, rather than being a primary disease state,
virtually all disorders that affect pulmonary vascu-
lature may cause PH. Pulmonary arterial hyperten-
sion (PAH), which forms group 1 of the Venice clas-
sification, constitutes a group of disorders that are
characterized by hypertrophic and thrombotic ob-
structive changes in the pulmonary arterial tree [2,
3]. Platelet abnormalities and abnormal platelet
activation are important mediators of disease pro-
gression, as they both contribute to thrombotic
obstruction of pulmonary arteries and induce ves-
sel remodeling [4]. Other causes of PH, such as left
ventricular failure (LVF) or chronic lung diseases,
have different pathogenetic mechanisms that lead
to PH, while in advanced stages they may cause
similar changes in pulmonary vasculature including
vessel remodeling [5]. The role of platelets in the
development of PH in these patients is less well
defined.
Mean platelet volume (MPV) is a well-studied
marker of abnormal platelet activity [6]. Increased
mean platelet volumes correspond to enhanced
platelet reactivity, as well as more secretion of
platelet-derived mediators such as 5-hydroxy-
-triptamine that induce smooth muscle cell prolife-
ration [7, 8]. MPV values are increased in a num-
ber of disease states, including myocardial infarc-
tion, unstable angina, and stroke [9]. Recently, MPV
levels have been shown to be increased in patients
with PAH [10].
In this study, we aimed to retrospectively ob-
serve and compare MPV levels and total thrombo-
cyte counts in patients with different etiologies for
PH and in normal controls.
Methods
Databases from a PH clinic, a cardiac transplan-
tation clinic and a pulmonary diseases clinic were
reviewed for patients with PH of any cause. PH is
defined as an echocardiographically measured peak
tricuspid regurgitant velocity of more than 3.4 m/s
and calculated systolic PAP of more than 50 mm Hg.
Patients who were more than 18 years old, had PH
as defined above, and at least one complete blood
count obtained at admission were included in the
analysis. Those with known disorders of the coagu-
lation system, liver dysfunction or renal failure
were excluded from analysis. A total of 67 patients
were included. PH patients with idiopathic PAH,
PAH secondary to congenital heart disease or sys-
temic disorders formed the PAH group, which con-
sisted of 26 patients. The PH due to congestive
heart failure (LVFPH) group consisted of eligible
patients with a left ventricular ejection fraction of
less than 40%, and who had PH as defined above.
This group comprised 26 patients. Fifteen patients
with a forced expiratory volume in first second to
forced vital capacity ratio (FEV1%) of less than 75%,
and who had PH as defined above with no other ap-
parent cause that may caused PH, formed the PH
secondary to chronic obstructive pulmonary disease
(COPDPH) group. A random 31 patients who were
referred to echocardiography for other reasons who
had calculated peak PAP below 36 mm Hg and peak
tricuspid velocity of less than 2.8 m/s served as
healthy controls, in whom PH was not considered.
For all patients, MPV and total thrombocyte
count values were obtained from first complete
blood count (in EDTA) that was performed by
a Coulter counter (Gen-S, Coulter Corporation, Mia-
mi, FL, USA) on admission to our institution. Data
was recorded regarding age, gender, past medical
records and medications at the time of initial mea-
surements. Peak PAP and maximal tricuspid regur-
gitation flow velocities were obtained from the first
echocardiographic examination that was measured
using a Vivid 3 (GE Healthcare, Piscataway, NJ,
USA) system equipped with a 2.5 MHz phased ar-
ray transducer, which is standard equipment in an
institutional echocardiography laboratory.
Appropriate permissions were obtained from
institutional science and ethics commissions for this
study.
Statistical analysis
Statistical analyses were performed using
SPSS v.13 software (formerly SPSS Inc., Chicago,
IL, USA). Results were expressed as the mean ±
± SD. We used Kolmogorov-Smirnov and Levene
tests to determine the distribution characteristics
of variables and variance homogeneity. Independent
samples Student’s t test or Mann-Whitney U test
was used, as appropriate, to determine differences
for continuous variables between two groups. One-
-way ANOVA was used to test statistically signifi-
cant differences when more than two independent
groups were present and variances were equal,
while Kruskal-Wallis test was used when equal varia-
nces were not present. Post-hoc analysis was per-
formed with Scheffe and Mann-Whitney U tests ac-
cording to tested variables. Pearson’s R was used for
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correlation analysis of linear variables when appro-
priate. Multiple regression analysis (with dummy
variables) was used when more than one variable was
found to influence MPV values. A p value of less than
0.05 was accepted as statistically significant, while
correlation was said to be present when r value was
more than 0.25.
Results
Demographic variables, past medical history,
medications and laboratory findings for PH patients,
PH subgroups and healthy controls are set out in
Tables 1 and 2. Age and gender did not differ be-
tween PH patients and healthy controls, while sub-
group analyses revealed statistically significant dif-
ferences between subgroups (Table 2). Systo-
lic PAP was significantly higher in the PH group
(70.16 ± 24.09 mm Hg) compared to the controls
(22.77 ± 4.29; p < 0.001); while PAH (90.31 ±
± 26.44 mm Hg) patients had significantly increased
PAP compared to other PH subgroups (p < 0.001).
Patients with PH used drugs that affect the coagu-
lation system significantly more than the control
group (49% vs 29% for antiaggregants and 28% vs
4% for anticoagulants; p < 0.05 for both); while sig-
nificance did not persist for anticoagulant usage af-
ter excluding idiopathic PAH. There was no statis-
Table 1. Demographic and laboratory data of pulmonary hypertension and control groups.
Parameter Pulmonary hypertension group Control group P
(n = 67) (n = 31)
Demographic variables
Age [years] 44.54 ± 15.94 42.58 ± 11.78 0.54
Gender (%male)  65% 45% 0.055
Past medical history
Systemic hypertension 46% 41% 0.67
Diabetes mellitus 18% 15% 0.75
Hyperlipidemia 25% 26% 0.89
Smoking history 32% 30% 0.86
Coronary heart disease 19% 19% 0.93
Congenital heart disease 32% 4% < 0.01
Systemic inflammatory disease 2% 0% 1
Previous medications
Antiaggregants 49% 24% < 0.05*
Anticoagulants 28% 4% < 0.05**
ACE inhibitors/ARBs 43% 36% 0.58
Beta-blockers 43% 16% < 0.05
Calcium channel blockers 24% 8% 0.21
Diuretics 46% 4% < 0.001
Digitalis compounds 28% 0% < 0.01
Inhaled corticosteroids 13% 0% 0.09
Inhaled beta agonists 11% 0% 0.17
Theophylline 13% 0% 0.09
Laboratory and echocardiographic data
Systolic PAP [mm Hg] 70.16 ± 24.09 22.77 ± 4.29 < 0.001
Mean platelet volume [fL] 8.77 ± 1.18 7.89 ± 0.53 < 0.001
TTC [× 103/mm3] 234.10 ± 71.10 261.61 ± 59.01 0.064
PDW [%] 16.58 ± 0.81 16.27 ± 1.18 0.17
Hemoglobin [g/dL] 14.57 ± 0.57 13.8 ± 1.66 0.14
RBC count [× 106/mm3] 5.15 ± 0.94 4.44 ± 0.56 < 0.001
MCV [fL] 85.61 ± 7.73 89.06 ± 5.57 < 0.05
RDW [%] 16.4 ± 3.65 14.02 ± 2.06 < 0.001
Data is given as ± standard deviation; *statistical significance persists after pulmonary arterial hypertension patients are excluded; **is not statisti-
cally significant when pulmonary arterial hypertension patients are excluded; ACE — angiotensin converting enzyme; ARB — angiotensin receptor
blocker; PAP — pulmonary artery pressure; TTC — total thrombocyte count; PDW — platelet distribution width; RBC — red blood cell count;
MCV — mean cytosolic volume; RDW — red cell distribution width
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tically significant difference between the LVFPH
(58.19 ± 7.00 mm Hg) and the COPDPH (56.00 ±
± 12.84 mm Hg) groups, while both groups had
elevated PAP compared to controls (p < 0.001).
Individual groupings for past medical history
and drug usage had identified history of coronary
artery disease, history of congenital heart malfor-
mations, usage of anticoagulant drugs, endothelin
receptor antagonists or digoxin as factors that may
affect MPV in patients and controls. Multiple re-
gression analysis had shown the presence of PH as
an individual marker for increased MPV (p = 0.009)
and statistical significance persisted even after ex-
clusion of idiopathic PAH patients (p = 0.017). Oth-
er independent variables that had an effect on MPV
were history of coronary artery disease, and medi-
cations including endothelin receptor antagonists
and digoxin.
Mean platelet volume was higher in the PH
group compared to normal controls (8.77 ± 1.18 vs
7.89 ± 0.53; p < 0.001) (Table 1, Fig. 1A). This find-
ing was still statistically significant when PAH pa-
tients were excluded from the PH group (8.59 ±
± 1.23 vs 7.89 ± 0.53; p < 0.001) (Fig. 1B). Total
thrombocyte count was higher in normal controls
than PH patients, while this finding had no statisti-
cal significance (261.61 × 103 ± 59.01 × 103 vs
234.10 × 103 ± 71.10 × 103; p > 0.05). When in-
dividual groups were considered, significant differe-
nces existed between groups (p < 0.001). Post hoc
analysis of individual groups showed that patients
in the PAH (9.05 ± 1.05 fL) and LVFPH (8.82 ± 1.27 fL)
subgroups had higher MPV values than healthy
controls (7.89 ± 0.52 fL, p < 0.001 and p < 0.05;
respectively). Additionally, MPV values were sig-
nificantly elevated in the PAH group compared to
the COPDPH group (9.05 ± 1.05 fL vs 8.05 ± 0.97 fL,
p < 0.05). While mean MPV was elevated in the
COPDPH group compared to the control group, this
finding had no statistical significance (8.05 ± 0.97 fL
vs 7.89 ± 0.52 fL, p > 0.05). There were no statis-
tically significant differences between groups when
total thrombocyte count was considered (p > 0.05)
(Table 2, Fig. 2).
In patients with known PAH, MPV did not cor-
relate with systolic PAP (r = 0.13; p > 0.05), or
age (r = –0.12; p > 0.05); while a weak negative
correlation was present between MPV and throm-
bocyte count (r = –0.26; p < 0.05) (Fig. 3).
Discussion
This study showed that patients with PH, when
considered as a group, have higher mean platelet vo-
lume compared to normal controls, and that those pa-
tients with PH but not PAH had higher mean platelet
volume compared to normal controls. Subgroup ana-
lysis showed patients with PH caused by PAH or LVF
had higher MPV values compared to normal controls.
While MPV was higher in the PH group, no correla-
tion was present between MPV and peak PAP.
The role of platelets in the development and
progression of PAH is well established. Platelets
are an integral part of the coagulation system that
contributes to thrombotic pulmonary arteriopathy
[3, 4]. Platelets appear to be activated during pul-
monary transit, and they may contribute to throm-
bin and clot generation [11]. Moreover, mediators
Table 2. Demographic and laboratory findings in pulmonary hypertension subgroups and healthy controls.
Parameter Pulmonary hypertension group (n = 67) Control group
PAH (n = 26) LVFPH (n = 26) OPDPH (n = 15)
Gender (%male) 31% 88%** 87%* 45%
Age [years] 36.42 ± 12.75 41.27 ± 10.83 64.27 ± 11.81** 42.58 ± 11.78
Systolic PAP [mm Hg] 90.31 ± 26.44**  58.19 ± 7.00** 56.00 ± 12.84**  22.77 ± 4.29
Mean platelet volume [fL]  9.06 ± 1.05**  8.83 ± 1.27**  8.19 ± 1.08  7.89 ± 0.53
TTC [× 103/mm3] 225.77 ± 72.46 234.12 ± 68.09 248.53 ± 76.32 261.61 ± 59.01
PDW [%] 16.60 ± 0.85 16.56 ± 0.51 16.56 ± 1.16 16.28 ± 1.18
Hb [g/dL] 15.33 ± 3.14 13.89 ± 2.28 14.50 ± 2.19 13.80 ± 1.66
RBC [× 106/mm3] 5.59 ± 0.96** 4.80 ± 0.68* 5.02 ± 1.06 4.44 ± 0.57
MCV [fL] 83.96 ± 9.14* 85.19 ± 4.55** 89.19 ± 8.74 89.06 ± 5.57
RDW [%] 17.37 ± 4.47** 16.00 ± 3.04** 15.39 ± 2.75* 14.01 ± 2.06
Data is given as ± SD; *difference is significant at p < 0.05 level compared to control group; **difference is significant at p < 0.01 level compared to
control group; PAH — pulmonary arterial hypertension; LVFPH — pulmonary hypertension due to left ventricular failure; COPDPH — pulmonary hy-
pertension due to chronic obstructive pulmonary disease; PAP — pulmonary artery pressure; TTC — total thrombocyte count; PDW — platelet distri-
bution width; RBC — red blood cell count; MCV — mean cytosolic volume; RDW — red cell distribution width
(n = 31)
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liberated from thrombocytes, such as seratonin and
platelet derived growth factor, stimulate smooth
muscle cell proliferation and medial hypertrophy
[12, 13]. High plasma seratonin levels were found
in patients with primary PH, which was responsive
to epoprostenol [12]. Interestingly, platelets of pa-
tients with PAH appear to contain smaller amounts
of seratonin compared to healthy controls. In their
article, the authors suggested that this finding may
imply that degranulation during pulmonary transit
could be responsible for the unexpectedly low plate-
let seratonin content [14]. Findings from an experi-
ment using a hypoxic model of PH, in which a de-
crease in mean platelet volume was observed after
pulmonary passage that is compatible with platelet
degranulation, further supports this hypothesis [15].
Increased mean platelet volume reflects heigh-
tened platelet activity. Large platelets are more
reactive and produce more prothrombotic com-
pounds [6]. They also contain more dense granules
and 5' hydroxytriptamine [7, 8]. Relationship of
MPV with a variety of cardiovascular conditions,
including myocardial infarction and stroke, are well
established [9]. Recently, Can et al. [10] have shown
increased MPV values in patients with PAH, along
with an enhanced aggregation in response to ade-
nosine diphosphate. Similarly, we found increased
MPV values in patients with PAH, and this increase
Figure 1. Mean platelet volume values in the pulmonary hypertension (PH) group and healthy controls (A). Difference
was statistically significant at p < 0.001 level. Mean platelet volume values in the PH group after exclusion of pulmonary
arterial hypertension patients compared with healthy controls (B). Difference was statistically significant at p < 0.001
level.
Figure 2. Mean platelet volume values in the pulmona-
ry hypertension subgroups and healthy controls. Stati-
stically significant differences existed between the pul-
monary arterial hypertension (PAH) group and the pul-
monary hypertension due to left ventricular failure
(LVFPH) group compared to healthy controls. Mean pla-
telet volume values were also significantly increased in
the PAH group compared to the pulmonary hypertension
due to chronic obstructive pulmonary disease group
(COPDPH).
A B
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Figure 3. Linear regression analysis results between mean
platelet volume (MPV) and pulmonary artery pressure
(PAP) (A), age (B), and total thrombocyte count (C). The
only statistically significant correlation was between total
thrombocyte count and mean platelet volume (p < 0.05).
was only weakly related to total thrombocyte count,
thereby suggesting a primary abnormality rather
than a response to total thrombocyte number.
The pathophysiology of PH observed in pa-
tients with LVF or COPD is different from PAH,
and is thought to be the result of underlying dise-
ase state rather than primary reactive changes in
the pulmonary arterial tree. However, there are cer-
tain pathophysiological similarities, such as arteri-
al vasoconstrictive response and trophic changes in
arterioles in patients with PH caused by LVF and
COPD [2, 16]. As these responses are partly eluci-
dated by platelets or mediators released by plate-
lets in patients with PAH, it is reasonable to con-
sider that platelet activation may play a role in oth-
er forms of PH. Indeed, we found that MPV values
of patients in the PH group were increased com-
pared to healthy controls, even when the PAH
group was excluded. This finding implies general-
ized platelet activation in all causes of PH is present,
and this may contribute to progression of PH, even
if it is not the cause of PH itself.
Platelet activation in patients with PH due to
LVF or COPD may be caused by PH itself or by the
underlying disease state [17–19]. In both of these
conditions, however, platelet activation may lead to
a further increase in pulmonary vascular resistance.
It has been shown that patients with LVF exhibit
increased platelet activation [18], and increased
MPV values in patients with LVF predicted left
ventricular thrombosis [20]. Previous studies also
indicated that patients with COPD have increased
MPV values, especially in those with known PH [19,
21]. In our study, subgroup analysis revealed in-
creased MPV levels in patients with PH caused by
LVF. While MPV levels in the COPD group were
higher compared to normal controls, this finding did
not reach statistical significance. This contradiction
of our results with previous studies may be due to
the relatively small number of COPD patients in-
cluded in this analysis.
While our results indicate that patients with PH
exhibit increased MPV values compared to controls,
MPV values do not correlate with systolic PAP in
patients with PH. It is possible that activation of
platelets can be a generalized primary response in
all types of PH and can be independent of disease
severity. Also, different etiologies for PH may also
cause different MPV values, as underlying disease
also has an effect on the degree of platelet activa-
tion and MPV. Another possible explanation for that
finding is that the echocardiographic measurement
of PAP may not be sufficiently precise to determine
a correlation between MPV values and PAP [22].
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According to current guidelines, oral anticoagu-
lation is considered as a treatment option to halt the
progress of PH in PAH patients [22]. Some studies
have found coumadine has an impact on disease
outcome, while others have not [4]. In addition,
a small study found aspirin and clopidogrel effec-
tively inhibits platelet aggregation, while aspirin
was also effective in decreasing thromboxane syn-
thesis without affecting prostacycline production
[23]. Except for the PAH group, anticoagulation is
currently not recommended in PH patients if an-
other indication does not exist [22].
Limitations of the study
As this study was retrospective in nature, ob-
tained MPV values are subject to measurement er-
rors; it has previously been shown that MPV tends
to increase when withdrawn blood has spent more
than two hours in EDTA. However, institutional
procedures dictate blood should be collected in
EDTA and should be analyzed within two hours of
collection. While we consider procedural errors to
have been minimal, no absolute guarantees can be
provided.
Similarly, peak tricuspid regurgitant velocity
and PAP measurements were obtained from previ-
ously performed echocardiographic investigations.
As institutional laboratories use the same echocar-
diography devices (GE Vivid 3) and probes, and all
measurements were made by expert echocardio-
graphers, these effects should be minimal. Because
measurements were performed by different
echocardiographers, peak PAP measurements were
subject to interobserver variability. We consider
that peak PAP, a marker of disease severity, can
be affected by this fact rather than a diagnosis of
PH. It is more frequent to mistakenly measure
a peak velocity as being below the actual figure, so
those measured above predefined limits were prob-
ably correct.
A final limitation arises from the fact that
echocardiographic measurement of PAP is not con-
sidered as a gold standard measurement for diag-
nosis of PH. Still, echocardiographically measured
peak PAP of more than 50 mm Hg, combined with
a maximal tricuspid regurgitant velocity of more
than 3.4 m/s, are considered as diagnostic under Eu-
ropean guidelines [22]. Also, cardiac catheterization
does not alter treatment options in patients with
LVF or COPD, so it would not be ethical to mea-
sure pulmonary pressure invasively in these pa-
tients.
Conclusions
We have shown that mean platelet volume is
higher in patients with PH, even when patients with
PAH are excluded. This finding implies platelet
activation occurs in all patients with PH, with pos-
sible pathophysiologic similarities regarding plate-
let-mediated progression of PH between PAH and
other causes of PH.
Further studies are needed to address the role
of platelets in patients with PH, especially those
with PH caused by etiologies different from PAH,
and the possible role of treatments specifically tar-
geting platelet activation.
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